Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureYaxin Fan, Lin Xi, Hailan Wu, Nanyang Li, Qiyu Bian, Huajun Zheng, Yongqiang Zhu, Jufang Wu, Beining Guo
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK
10.1093/jacamr/dlaa114 · 2021
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications
10.1128/cmr.00042-09 · 2010
Reduced susceptibility and resistance to vancomycin of Staphylococcus aureus: A review of global incidence patterns and related genetic mechanisms
2021
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
10.1038/s41598-020-69058-z · 2020
Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold
10.1038/s41467-025-66118-8 · 2025
Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bloodstream infection
10.1128/aac.00380-13 · 2013
Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years
10.1128/jcm.02135-08 · 2009
Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997-2021): a systematic review and meta-analysis
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.jgar.2024.02.002 · 2024
Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method
10.1128/jcm.01128-10 · 2011
10.1093/cid/ciaa303
10.1093/cid/ciaa303 · 2020
Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus
10.1016/j.ijantimicag.2010.12.007 · 2011
Sequence type 5 (ST5) as a possible predictor of bacterial persistence in adult patients with methicillin-resistant Staphylococcus aureus pneumonia treated with vancomycin
10.1128/spectrum.01348-22 · 2022
Comparative efficacy of vancomycin in treating ST5 and ST764 methicillin-resistant Staphylococcus aureus infections in adult patients
10.1128/msphere.00457-23 · 2023
Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China
10.1128/aac.00206-09 · 2009
Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study
10.1186/s13756-022-01140-9 · 2022
Genotype-specific prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in Asian countries
10.1016/j.ijantimicag.2015.03.009 · 2015
Resistance and molecular characteristics of methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate Staphylococcus aureus
10.2147/idr.s392908 · 2023
CLSI performance standards for antimicrobial susceptibility testing
2022
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital
10.1093/jac/47.4.399 · 2001
Velvet: algorithms for de novo short read assembly using de Bruijn graphs
10.1101/gr.074492.107 · 2008
High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China
10.1093/jac/dkz232 · 2019
Prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus isolated from hospitalized patients
10.3343/alm.2016.36.3.235 · 2016
Investigation of heteroresistant vancomycin intermediate Staphylococcus aureus among MRSA isolates
10.3855/jidc.12799 · 2021
qacA is a key factor in heteroresistance to vancomycin in sequence type 5 methicillin-resistant Staphylococcus aureus isolates from pneumonia patients
2026
beta-Lactam combinations with vancomycin show synergistic activity against vancomycin-susceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA
10.1128/aac.00157-18 · 2018
Combination antibiotic exposure selectively alters the development of vancomycin intermediate resistance in Staphylococcus aureus
10.1128/aac.02100-17 · 2018
Predominance of ST5-II-t311 clone among healthcare-associated methicillin-resistant Staphylococcus aureus isolates recovered from Zhejiang, China
10.1016/j.ijid.2018.04.798 · 2018
Using core-genome multilocus sequence typing to monitor the changing epidemiology of methicillin-resistant Staphylococcus aureus in a teaching hospital
10.1093/cid/ciy644 · 2018
Prevalence and WGS-based characteristics of MRSA isolates in hospitals in Shanghai
2022
Dissemination of methicillin-resistant Staphylococcus aureus sequence type 764 isolates with mupirocin resistance in China
10.1128/spectrum.03794-22 · 2023
Trends in the minimum inhibitory concentrations for four agents against methicillin-resistant Staphylococcus aureus in bloodstream infections in China: a 6-year multi-center study from 2017 to 2022
10.1016/j.dcit.2025.100052 · 2025
No additional external references are available.